TELA Bio, Inc. (TELA) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

8/25

Growth 1 Margin 3 Expansion 3 Platform 0 Financial 1

latest quarter score

Earnings Reports

8
TELA Bio (TELA) Q2 2026: International Revenue Up 26% Amid PRS Volume Challenges
August 11, 2026
14
Telebio (TELA) Q1 2026: 41% International Surge Validates Commercial Reset and Portfolio Expansion
May 13, 2026
20
Telebio (TELA) Q4 2025: 40% New Rep Cohort Drives Commercial Reset, 8% Growth Guide Signals Cautious Ramp
March 25, 2026
17
Telebio (TELA) Q3 2025: Salesforce Expands to 76 Territory Managers, Driving Foundation for 15%+ Growth
November 14, 2025
21
TELA Bio (TELA) Q2 2025: PRS Revenue Jumps 53% as Patient-Centric Model Reshapes Growth Trajectory
August 11, 2025
12
Telebio (TELA) Q1 2025: 12% Revenue Growth Reflects Commercial Realignment and Market Expansion
May 08, 2025
14
TELA Bio (TELA) Q4 2024: Sales Force Disruptions Weigh on Growth Despite Market Expansion
March 21, 2025

Browse all companies